First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies
Based on the rapid recovery of transient thrombocytopenia that occurred only in the first cycle and the degradation of BCL-XL in peripheral leukocytes, the RP2D of DT2216 is 0.4 mg/kg IV BIW. (NCT04886622).
Authors
- Devalingam Mahalingam (ORCID: https://orcid.org/0000-0002-2979-9894)
- John Harkey
- Stacy Suberg
- Minal Barve (ORCID: https://orcid.org/0009-0007-4259-7457)
- James Strauss (ORCID: https://orcid.org/0000-0001-6414-6998)
- Robert Hromas (ORCID: https://orcid.org/0000-0002-1916-6276)
- Lisa J. Zimmerman (ORCID: https://orcid.org/0000-0002-4756-7616)
- Larry M. Tremaine
- Guangrong Zheng (ORCID: https://orcid.org/0000-0002-8106-6663)
- Daohong Zhou (ORCID: https://orcid.org/0000-0002-2400-6461)
- Daruka Mahadevan
- Jay Parekh
- J A Sills
- Michael R. Kurman
- J. R. McCulloch
Institutions
- Sarah Cannon Research Institute (GB)
- University of Florida (US)
- Indo-American Center (US)
- Sarah Cannon (US)
- Cancer Services (US)
- Diapin Therapeutics (United States) (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mays Cancer Center at UT Health San Antonio (US)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s13045-025-01753-8
- Citations
- 5
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.85
Funders
- National Institutes of Health